Cancer in primary immunodeficiency diseases: Cancer incidence in the United States Immune Deficiency Network Registry - 07/03/18
Abstract |
Background |
We evaluated the overall and site-specific incidence of cancer in subjects with primary immunodeficiency diseases (PIDD) enrolled in the United States Immune Deficiency Network (USIDNET) registry compared with age-adjusted cancer incidence in the Surveillance, Epidemiology and End Results Program (SEER) database.
Objective |
We hypothesized that subjects with PIDD would have an increased incidence of cancer due to impaired immune function.
Methods |
Overall and site-specific cancer incidence rates were evaluated in subjects with PIDD (n = 3658) enrolled in the USIDNET registry from 2003 to 2015 and compared with age-adjusted incidence rates in the SEER database.
Results |
We observed a 1.42-fold excess relative risk of cancer in subjects with PIDD compared with the age-adjusted SEER population (P < .001). Men with PIDD had a 1.91-fold excess relative risk of cancer compared with the age-adjusted male population (P < .001), while women with PIDD had similar overall cancer rates compared with the age-adjusted female population. Of the 4 most common malignancies in men and women in SEER (lung, colon, breast, and prostate cancers), we found no significant increase in these diagnoses in subjects with PIDD. Significant increases in lymphoma in both men (10-fold increase, P < .001) and women (8.34-fold increase, P < .001) with PIDD were observed.
Conclusions |
Excess incidence of cancer occurred in subjects with PIDD. An excess of lymphoma in specific PIDD populations principally drove this increased incidence, while no increased risk of the most common solid tumor malignancies was observed. These data point to a restricted role of the immune system in protecting from specific cancers.
Le texte complet de cet article est disponible en PDF.Key words : Cancer, common variable immunodeficiency, leukemia, lymphoma, primary immunodeficiency disease, USIDNET
Abbreviations used : CVID, HPV, IRB, PIDD, SEER, USIDNET, WAS
Plan
| Supported by Roswell Park Cancer Institute National Cancer Institute Cancer Center support grants (P30CA016056, 5T32CA108456 [to P.C.M.], NLM K01LM012100 [to K.E.], T32CA085183 [to K.L.S.], R01CA140622 [to S.I.A.], P50 CA159981 [to K.O.], R01CA188900 [to B.H.S. and K.B.M.]), and the United States Immunodeficiency Network and Immune Deficiency Foundation (U24AI086037-06). |
|
| This work was presented at the American Society of Clinical Oncology annual meeting in Chicago, IL June 3-7, 2016, as a poster discussion session. |
|
| Disclosure of potential conflict of interest: B. Segal's and P. Mayor's institutions received a grant from the National Institutes of Health (NIH) for this work. K. Eng's institution received NIH grant K01LM012100 for this work. K. Singel's institution received a grant from NIH. R. Fuleihan's institution received consultancy fees from CSL Behring and Shire, and payment for lectures from Shire. H. Ochs' institution received a grant from Jeffrey Modell Foundation. F. Bonilla personally received consultancy fees from CSL Behring, Grand Rounds Health Immune Deficiency Foundation, Advance Medical Consultation, Charles River Associates International, Green Cross, American Research Group, Guidepoint Global Advisors, Sarepta, Inc., and Health Resources Services Administration; payment for lectures from Brigham Board Review in Allergy and Immunology (Distance Learning) Course; royalties from UpToDate; and travel expenses from Immune Deficiency Foundation. R. Buckley is employed by Duke University Medical Center. K. Sullivan's institution received USIDNET subcontract from NIH; and K. Sullivan personally received consultancy fees from UpToDate and Immune Deficiency Foundation. Z. Ballas's institution received consultancy fees from Checkmate Pharmaceutical and grants from Checkmate Pharmaceutical for other works, and has a pending patent application using EGF level as a biomarker for response to ipilimumab; Z. Ballas personally received royalties from UpToDate C. Cunningham-Rundles's institute received U24 grant to the Immune Deficiency Foundation for USIDNET. The rest of the authors declare that they have no relevant conflicts of interest. |
Vol 141 - N° 3
P. 1028-1035 - mars 2018 Retour au numéro
Article précédent
- Sleep deprivation predisposes allergic mice to neutrophilic lung inflammation
- Jethe O.F. Nunes, Juliana de Souza Apostolico, David A.G. Andrade, Francieli S. Ruiz, Edgar R. Fernandes, Monica L. Andersen, Alexandre C. Keller, Daniela S. Rosa
- Long-term follow-up of IPEX syndrome patients after different therapeutic strategies: An international multicenter retrospective study
- Federica Barzaghi, Laura Cristina Amaya Hernandez, Benedicte Neven, Silvia Ricci, Zeynep Yesim Kucuk, Jack J. Bleesing, Zohreh Nademi, Mary Anne Slatter, Erlinda Rose Ulloa, Anna Shcherbina, Anna Roppelt, Austen Worth, Juliana Silva, Alessandro Aiuti, Luis Murguia-Favela, Carsten Speckmann, Magda Carneiro-Sampaio, Juliana Folloni Fernandes, Safa Baris, Ahmet Ozen, Elif Karakoc-Aydiner, Ayca Kiykim, Ansgar Schulz, Sandra Steinmann, Lucia Dora Notarangelo, Eleonora Gambineri, Paolo Lionetti, William Thomas Shearer, Lisa R. Forbes, Caridad Martinez, Despina Moshous, Stephane Blanche, Alain Fisher, Frank M. Ruemmele, Come Tissandier, Marie Ouachee-Chardin, Frédéric Rieux-Laucat, Marina Cavazzana, Waseem Qasim, Barbarella Lucarelli, Michael H. Albert, Ichiro Kobayashi, Laura Alonso, Cristina Diaz De Heredia, Hirokazu Kanegane, Anita Lawitschka, Jong Jin Seo, Marta Gonzalez-Vicent, Miguel Angel Diaz, Rakesh Kumar Goyal, Martin G. Sauer, Akif Yesilipek, Minsoo Kim, Yesim Yilmaz-Demirdag, Monica Bhatia, Julie Khlevner, Erick J. Richmond Padilla, Silvana Martino, Davide Montin, Olaf Neth, Agueda Molinos-Quintana, Justo Valverde-Fernandez, Arnon Broides, Vered Pinsk, Antje Ballauf, Filomeen Haerynck, Victoria Bordon, Catharina Dhooge, Maria Laura Garcia-Lloret, Robbert G. Bredius, Krzysztof Ka?wak, Elie Haddad, Markus Gerhard Seidel, Gregor Duckers, Sung-Yun Pai, Christopher C. Dvorak, Stephan Ehl, Franco Locatelli, Frederick Goldman, Andrew Richard Gennery, Mort J. Cowan, Maria-Grazia Roncarolo, Rosa Bacchetta, Primary Immune Deficiency Treatment Consortium (PIDTC) and the Inborn Errors Working Party (IEWP) of the European Society for Blood and Marrow Transplantation (EBMT)
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?